Contineum Therapeutics (CTNM)

• Market cap: $347M
• 1 day: 4.66%
• 5 days: 6.83%
• 1 month: 83.11%
• 3 months: 166.95%
• 6 months: 63.49%
• Year to date: -14.64%
• 1 year: -31.52%
• 5 years: -19.74%
• 10 years: -19.74%
• Sector: Healthcare
• Industry: Biotechnology

About: Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Employees: 41

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

35% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 20

11% more funds holding

Funds holding: 62 [Q1] → 69 (+7) [Q2]

6.62% less ownership

Funds ownership: 79.0% [Q1] → 72.39% (-6.62%) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]

45% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 22

48% less capital invested

Capital invested by funds: $106M [Q1] → $55.3M (-$50.3M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $21
• Avg. target: $21
• High target: $21

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Morgan Stanley Jeffrey Hung

$21

Overweight Maintained

18 Aug 2025